INCYIncyte CorporationSigning up patients
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Hematologic Malignancies
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 25 (planned)
- Started
- Nov 8, 2022
- Main results expected
- Aug 29, 2027
- Fully finished
- Aug 29, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Measured over: up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06465433 · record last updated 2025-12-10 · checked 2026-11-09 15:47 UTC